Company Wants To Fight Cancer Without So Much Damage To Healthy Cells
Maverick Therapeutics Inc. thinks it can engage the body’s own T cells to fight the disease.
San Francisco Business Times:
How Maverick CEO Jeanmarie Guenot Wants To Track Down, Defeat Tough-To-Treat Cancers
There are a lot of “dirty” cancer targets — even if a drug reaches its destination and kills cancer cells, the side effects to nearby healthy tissue are so damaging that there’s little net gain for the patient. So one of the pinnacles of cancer drug development is how to cleanly get to those dirty targets, and Maverick Therapeutics Inc. thinks it has found a way. (Leuty, 4/12)
In other news —
The San Diego Union-Tribune:
Neurocrine Shares Soar After Ingrezza Approval, More Hiring Planned
Neurocrine Biosciences stock closed up nearly 25 percent Wednesday, after the San Diego biotech company announced the approval of Ingrezza, its movement disorder drug. Neurocrine closed at $51.80, up $10.32, or 24.88 percent for the day. The company had announced the approval after end of trading Tuesday. At Tuesday’s closing, Neurocrine’s market value also jumped, to $4.5 billion. (Fikes, 4/12)
San Diego Union-Tribune:
Another Biotech Company Joins San Diego, Bringing $40 Million In New Money
Tapping into San Diego’s biotech talent pool, a Michigan-based developer of an experimental therapy for liver disease is moving its administrative headquarters here. Cirius Therapeutics of Kalamazoo also has hired three experienced biomedical executives in San Diego to lead the company in connection with the opening. (Fikes, 4/11)